DNA damage response as an anti-cancer barrier: Damage threshold and the concept of 'conditional haploinsufficiency'

Cell Cycle

Volumn 6, Issue 19, 2007, Pages 2344-2347

  Bartek, Jiri ^a   Lukas, Jiri ^a   Bartkova, Jirina ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

Author keywords

Cancer progression; Cellular senescence; Conditional haploinsufficiency; DNA damage checkpoint; DNA damage threshold; DNA repair; Genetic instability; Oncogenes

Indexed keywords

ATM PROTEIN; BRCA1 PROTEIN; BRCA2 PROTEIN; DNA; PROTEIN P53;

BREAST CARCINOMA; CANCER GRADING; CANCER GROWTH; CARCINOGENESIS; COLON CARCINOMA; DNA DAMAGE; DNA REPLICATION; HUMAN; LUNG CARCINOMA; REVIEW;

EID: 35848949304     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.6.19.4754     Document Type: Review

References (40)

1. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
2. Bartek J, Lukas J. DNA damage checkpoints: From initiation to recovery or adaptation. Current Opin Cell Biol 2007; 19:238-45.
3. Shiloh Y. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer 2003; 3:155-68.
4. Lukas J, Lukas C, Bartek J. Mammalian cell cycle checkpoints: Signalling pathways and their organization in space and time. DNA Repair 2004; 3:997-1007.
5. Bartek J, Lukas C, Lukas J. Checking on DNA damage in S phase. Nat Rev Mol Cell Biol 2004; 5:792-804.
6. Kastan M, Bartek J. Cell-cycle checkpoints and cancer. Nature 2004; 432:316-23.
7. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, ∅rntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
8. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, DiTullio Jr RA, Kastrinakis NG, Levy B, Klesas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
9. DiTullio RA, Mochan TA, Venere M, Bartkova J, Sehested M, Bartek J, Halazonetis TD. 53BP1 functions in an ATM-dependent checkpoint pathway that is constitutively activated in human cancer. Nat Cell Biol 2002; 4:998-1002.
10. Bartkova J, Bakkenist CJ, Rajpert-De Meyts E, Skakkebæk NE, Sehested M, Lukas J, Kastan MB, Bartek J. ATM activation in normal human tissues and testicular cancer. Cell Cycle 2005; 4:838-45.
11. Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Ørntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006; 444:633-7.
12. Di Micco R, Fumagalli M, Cicalese A, Piccini S, Gasparini P, Luise C, Shurra C, Garre M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG, d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006; 444:638-42.
13. Nuciforo PG, Luise C, Capra M, Pelosi G, d'Adda di Fagagna F. Complex engagement of DNA-damage response pathways in human cancer and in lung tumor progression. Carcinogenesis 2007; In press.
14. Fan C, Quan R, Feng X, Gillis A, He L, Matsumoto ED, Salama S, Cutz JC, Kapoor A, Tang D. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim Biophys Acta 2006; 1763:1090-7.
15. Mallette FA, Gaumont-Leclerc MF, Ferbeyre G. The DNA damage signalling pathway is a critical mediator of oncogene-induced senescence. Genes Dev 2007; 21:43-8.
16. Frame FM, Rogoff HA, Pickering MT, Cress WD, Kowalik TF. E2F1 induces MRN foci formation and a cell cycle checkpoint response in human fibroblasts. Oncogene 2006; 25:3258-66.
17. Powers JT, Hong S, Mayhew CN, Rogers PM, Knudsen ES, Johnson DG. E2F1 uses the ATM signalling pathway to induce p53 and Chk2 phosphorylation and apoptosis. Mol Cancer Res 2004; 2:203-14.
18. Sedelnikova O, Bonner WM. gH2AX in cancer cells: A potential biomarker for cancer diagnostics, prediction and recurrence. Cell Cycle 2006; 5:2909-13.
19. Tort F, Bartkova J, Sehested M, Orntoft T, Lukas J, Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res 2006; 66:10258-63.
20. Pusapati RV, Rounbehler RJ, Hong S, Powers JT, Yan M, Kiguchi K, McArthur MJ, Wong PK, Johnson DG. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Proc Natl Acad Sci USA 2006; 103:1446-51.
21. Reimann M, Loddenkemper C, Rudolph C, Schildhauer I, Teichmann B, Stein H, Schlegelberger B, Dorken B, Schmitt CA. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood 2007; In press.
22. Pickering MT, Kowalik TF. Rb inactivation leads to E2F1-mediated DNA double-strand break accumulation. Oncogene 2006; 25:746-55.
23. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. Nature 2003; 426:194-8.
24. Takai H, Smogorzewska A, de Lange T. DNA damage foci at dysfunctional telomeres. Curr Biol 2003; 13:1549-56.
25. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway and the restriction point. Current Opinion in Cell Biology 1996; 8:805-14.
26. Ruas M, Peters G. The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378:F115-77.
27. Bartkova J, Thullberg M, Slezak P, Jaramillo E, Rubio C, Thomassen LH, Bartek J. Aberrant regulation of G1-phase cell cycle regulators in flat and exophytic adenomas of the human colon. Gastroenterology 2001; 120:1680-8.
28. Bartek J, Lukas J, Bartkova J. Defects in cell cycle control and cancer. J Pathol 1999; 187:95-9.
29. Sarkisian CJ, Keister BA, Stairs DB, Boxer RB, Moody SE, Chodosh LA. Dose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis. Nat Cell Biol 2007; 9:493-505.
30. Bartkova J, Rajpert-De Meyts E, Skakkebæk NE, Lukas J, Bartek J. DNA damage response in human testes and testicular germ cell tumors: Biology and implications for therapy. J Androl 2007; 30:383-91.
31. Bartkova J, Horejsi Z, Sehested M, Nesland JM, Rajpert-De Meyts E, Skakkebæk NE, Stucki M, Jackson S, Lukas J, Bartek J. DNA damage response mediators MDC1 and 53BP1: Constitutive activation and aberrant loss in breast and lung cancer, but not in testicular germ cell tumours. Oncogene 2007; In press.
32. 1/S-phase control in human testicular germ cell tumours. APMIS 2003; 111:252-65.
33. Bartkova J, Lukas C, Sørensen CS, Rajpert-De Meyts E, Skakkebæk NE, Lukas J, Bartek J. Deregulation of the RB pathway in human testicular germ cell tumors. J Pathol 2003; 200:149-56.
34. Ward IM, Difilippantonio S, Minn K, Mueller MD, Molina JR, Yu X, Frisk CS, Ried T, Nussenzweig A, Chen J. 53BP1 cooperates with p53 and functions as a haploinsufficient tumor suppressor in mice. Mol Cell Biol 2005; 25:10079-86.
35. Celeste A, Difilippantonio S, Difilippantonio MJ, Fernandez-Capetillo O, Pilch DR, Sedelnikova OA, Eckhaus M, Ried T, Bonner WM, Nussenzweig A. H2AX haploinsufficiency modifies stability and tumor susceptibility. Cell 2003; 114:371-83.
36. Cressman VL, Backlund DC, Hicks EM, Gowen LC, Godfrey V, Koller BH. Mammary tumor formation in p53- and BRCA1-deficient Mice. Cell Growth and Differentiation 1999; 10:1-10.
37. Cao L, Kim S, Xiao C, Wang RH, Coumoul X, Wang X, Li WM, Xu XL, De Soto JA, Takai H, Mai S, Elledge SJ, Motoyama N, Deng CX. ATM-Chk2-p53 activation prevents tumorigenesis at an expense of organ homeostasis upon Brca1 deficiency. EMBO J 2006; 25:2167-77.
38. Barwell J, Pangon L, Georgiou A, Kesterton I, Langman C, Arden-Jones A, Bancroft E, Salmon A, Locke I, Kote-Jarai Z, Morris JR, Solomon E, Berg J, Docherty Z, Camplejohn R, Eeeles R, Hodgson SV. Lymphocyte radiosensitivity in BRCA1 and BRCA2 mutation carriers and implications for breast cancer susceptibility. Int J Cancer 2007; 121:1631-6.
39. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, Smith GC, Ashworth A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434:917-21.
40. Bryant HE, Schultz N, Thomas HD, Parker KM, Flowed D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434:913-7.